Chemical formula: C₁₈H₂₂O₂ Molecular mass: 270.366 g/mol PubChem compound: 5870
Estrone should not be used during pregnancy.
Estrone hould not be used during lactation.
Long-term continuous administration of natural and synthetic estrogens in certain animal species increases the frequency of carcinomas of the breast, uterus, cervix, vagina, testis, and liver.
See Warnings and Precautions regarding potential induction of malignant neoplasms and adverse effects similar to those of oral contraceptives.
The following adverse reactions have been reported with estrogen/progestin combination in general:
Blood and lymphatic system disorders: Altered coagulation tests (see: Warnings and Precautions, Drug-Laboratory Tests Interactions).
Cardiac disorders: Palpitations; increase in blood pressure (see Warnings and Precautions); coronary thrombosis.
Endocrine disorders: Increased blood sugar levels; decreased glucose tolerance.
Eye disorders: Neuro-ocular lesions (e.g. retinal thrombosis, optic neuritis); visual disturbances; steepening of the corneal curvature; intolerance to contact lenses.
Gastrointestinal disorders: Nausea; vomiting abdominal discomfort (cramps, pressure, pain, bloating).
General disorders and administration site conditions: Fatigue; changes in appetite; changes in body weight; change in libido.
Hepatobiliary disorders: Gallbladder disorder; asymptomatic impaired liver function; cholestatic jaundice.
Musculoskeletal and connective tissue disorders: Musculoskeletal pain including leg pain not related to thromboembolic disease (usually transient, lasting 3-6 weeks) may occur.
Nervous system disorders: Aggravation of migraine episodes; headaches; dizziness; neuritis.
Psychiatric disorders: Mental depression; nervousness; irritability.
Renal and urinary disorders: Cystitis; dysuria; sodium retention; edema.
Reproductive system and breast disorders: Breakthrough bleeding; spotting; change in menstrual flow; dysmenorrhea; vaginal itching/discharge; dyspareunia; endometrial hyperplasia; pre-menstrual-like syndrome; reactivation of endometriosis; changes in cervical erosion and amount of cervical secretion; breast swelling and tenderness.
Skin and subcutaneous tissue disorders: Chloasma or melasma, which may persist when drug is discontinued; erythema multiforme; erythema nodosum; haemorrhagic eruption; loss of scalp hair; hirsutism and acne.
Vascular disorders: Isolated cases of: thrombophlebitis; thromboembolic disorders.
Clinical Trial Adverse Drug Reactions: Data are not available.
Less Common Clinical Trial Adverse Drug Reactions: Data are not available.
Case #1- Complaint of a burning sensation.
Case# 2- Complaint of inflammation and vaginal discharge.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
